{
  "currency": "USD",
  "company_name": "Cumberland Pharmaceuticals Inc.",
  "metrics": {
    "Revenue": {
      "2024": 38,
      "2023": 40,
      "2022": 42,
      "2021": 36,
      "2020": 37
    },
    "Revenue Growth": {
      "2024": "-4.3%",
      "2023": "-5.9%",
      "2022": "16.7%",
      "2021": "-3.9%",
      "2020": "8.9%"
    },
    "Gross Profit": {
      "2024": 26,
      "2023": 33,
      "2022": 33,
      "2021": 27,
      "2020": 29
    },
    "Gross Margin": {
      "2024": 0.7,
      "2023": 0.85,
      "2022": 0.78,
      "2021": 0.76,
      "2020": 0.77
    },
    "EBITDA": {
      "2024": 0,
      "2023": 0,
      "2022": 0,
      "2021": -1,
      "2020": -2
    },
    "EBITDA Margin": {
      "2024": 0.0,
      "2023": 0.0,
      "2022": 0.01,
      "2021": -0.02,
      "2020": -0.04
    },
    "FCF": {
      "2024": -1,
      "2023": 6,
      "2022": 6,
      "2021": 6,
      "2020": 3
    },
    "FCF Conversion": {
      "2024": 0.12,
      "2023": -0.9,
      "2022": -1.13,
      "2021": -1.07,
      "2020": -0.5
    },
    "ROIC": {
      "2024": "-14.3%",
      "2023": "-11.6%",
      "2022": "-9.0%",
      "2021": "-11.7%",
      "2020": "-8.7%"
    },
    "EV/EBITDA": {
      "2024": 196.97,
      "2023": 167.64,
      "2022": 102.03,
      "2021": -68.34,
      "2020": -23.79
    },
    "PE Ratio": {
      "2024": -5.14,
      "2023": -4.08,
      "2022": -5.8,
      "2021": -12.44,
      "2020": -6.75
    },
    "PB Ratio": {
      "2024": 1.46,
      "2023": 0.86,
      "2022": 0.9,
      "2021": 1.63,
      "2020": 0.95
    },
    "CFO": {
      "2024": -1,
      "2023": 6,
      "2022": 8,
      "2021": 6,
      "2020": 5
    }
  }
}